nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluvoxamine—SLC6A3—attention deficit hyperactivity disorder	0.552	0.572	CbGaD
Fluvoxamine—SLC6A4—attention deficit hyperactivity disorder	0.413	0.428	CbGaD
Fluvoxamine—SLC6A3—Clearance of dopamine—COMT—attention deficit hyperactivity disorder	0.00271	0.0928	CbGpPWpGaD
Fluvoxamine—SLC6A3—Clearance of dopamine—MAOA—attention deficit hyperactivity disorder	0.00269	0.0922	CbGpPWpGaD
Fluvoxamine—SLC6A4—Serotonin Transporter Activity—TPH2—attention deficit hyperactivity disorder	0.00208	0.0711	CbGpPWpGaD
Fluvoxamine—SLC6A4—Serotonin Transporter Activity—MAOA—attention deficit hyperactivity disorder	0.00125	0.0428	CbGpPWpGaD
Fluvoxamine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—COMT—attention deficit hyperactivity disorder	0.00124	0.0423	CbGpPWpGaD
Fluvoxamine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—MAOA—attention deficit hyperactivity disorder	0.00123	0.0421	CbGpPWpGaD
Fluvoxamine—SLC6A3—Alpha-synuclein signaling—STUB1—attention deficit hyperactivity disorder	0.00117	0.0399	CbGpPWpGaD
Fluvoxamine—SLC6A4—Monoamine Transport—TPH2—attention deficit hyperactivity disorder	0.000884	0.0303	CbGpPWpGaD
Fluvoxamine—SLC6A4—Monoamine Transport—HRH3—attention deficit hyperactivity disorder	0.00087	0.0298	CbGpPWpGaD
Fluvoxamine—SLC6A3—Monoamine Transport—TPH2—attention deficit hyperactivity disorder	0.000674	0.0231	CbGpPWpGaD
Fluvoxamine—SLC6A3—Monoamine Transport—HRH3—attention deficit hyperactivity disorder	0.000663	0.0227	CbGpPWpGaD
Fluvoxamine—SLC6A4—Monoamine Transport—SLC6A3—attention deficit hyperactivity disorder	0.00063	0.0216	CbGpPWpGaD
Fluvoxamine—SLC6A3—Monoamine Transport—SLC6A4—attention deficit hyperactivity disorder	0.000538	0.0184	CbGpPWpGaD
Fluvoxamine—SLC6A4—Synaptic Vesicle Pathway—SNAP25—attention deficit hyperactivity disorder	0.000487	0.0167	CbGpPWpGaD
Fluvoxamine—SLC6A3—forebrain—attention deficit hyperactivity disorder	0.000422	0.0642	CbGeAlD
Fluvoxamine—CYP1A2—Methylation—COMT—attention deficit hyperactivity disorder	0.000411	0.0141	CbGpPWpGaD
Fluvoxamine—CYP1A1—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.000402	0.0138	CbGpPWpGaD
Fluvoxamine—SLC6A4—forebrain—attention deficit hyperactivity disorder	0.000387	0.0589	CbGeAlD
Fluvoxamine—SLC6A3—Transmission across Chemical Synapses—GABRQ—attention deficit hyperactivity disorder	0.000304	0.0104	CbGpPWpGaD
Fluvoxamine—SLC6A3—midbrain—attention deficit hyperactivity disorder	0.000279	0.0424	CbGeAlD
Fluvoxamine—CYP1A1—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.000273	0.00934	CbGpPWpGaD
Fluvoxamine—CYP1A1—Oxidative Stress—MAOA—attention deficit hyperactivity disorder	0.000266	0.00909	CbGpPWpGaD
Fluvoxamine—SLC6A3—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.000258	0.00884	CbGpPWpGaD
Fluvoxamine—CYP1A2—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.000257	0.00878	CbGpPWpGaD
Fluvoxamine—SLC6A4—midbrain—attention deficit hyperactivity disorder	0.000256	0.0389	CbGeAlD
Fluvoxamine—SIGMAR1—midbrain—attention deficit hyperactivity disorder	0.000254	0.0386	CbGeAlD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.000249	0.00852	CbGpPWpGaD
Fluvoxamine—SLC6A3—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.000233	0.00797	CbGpPWpGaD
Fluvoxamine—SLC6A3—nervous system—attention deficit hyperactivity disorder	0.000229	0.0349	CbGeAlD
Fluvoxamine—CYP2C19—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.000223	0.00764	CbGpPWpGaD
Fluvoxamine—SLC6A3—central nervous system—attention deficit hyperactivity disorder	0.000221	0.0336	CbGeAlD
Fluvoxamine—SLC6A3—cerebellum—attention deficit hyperactivity disorder	0.000216	0.0328	CbGeAlD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.000214	0.00733	CbGpPWpGaD
Fluvoxamine—CYP2B6—cardiovascular system—attention deficit hyperactivity disorder	0.000212	0.0323	CbGeAlD
Fluvoxamine—CYP2C9—cardiovascular system—attention deficit hyperactivity disorder	0.00021	0.032	CbGeAlD
Fluvoxamine—SLC6A4—nervous system—attention deficit hyperactivity disorder	0.00021	0.0319	CbGeAlD
Fluvoxamine—CYP2D6—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.000205	0.00703	CbGpPWpGaD
Fluvoxamine—SLC6A4—Circadian rythm related genes—TPH2—attention deficit hyperactivity disorder	0.000203	0.00696	CbGpPWpGaD
Fluvoxamine—SLC6A4—central nervous system—attention deficit hyperactivity disorder	0.000202	0.0308	CbGeAlD
Fluvoxamine—CYP2E1—cardiovascular system—attention deficit hyperactivity disorder	0.000199	0.0303	CbGeAlD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.000199	0.00681	CbGpPWpGaD
Fluvoxamine—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.000198	0.00678	CbGpPWpGaD
Fluvoxamine—SIGMAR1—cerebellum—attention deficit hyperactivity disorder	0.000196	0.0299	CbGeAlD
Fluvoxamine—SLC6A4—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.000187	0.0064	CbGpPWpGaD
Fluvoxamine—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.000187	0.0284	CbGeAlD
Fluvoxamine—CYP3A7—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000181	0.0062	CbGpPWpGaD
Fluvoxamine—SLC6A3—brain—attention deficit hyperactivity disorder	0.000175	0.0266	CbGeAlD
Fluvoxamine—CYP1A2—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.000174	0.00596	CbGpPWpGaD
Fluvoxamine—SLC6A4—Circadian rythm related genes—DRD1—attention deficit hyperactivity disorder	0.000163	0.00556	CbGpPWpGaD
Fluvoxamine—SLC6A4—brain—attention deficit hyperactivity disorder	0.000161	0.0244	CbGeAlD
Fluvoxamine—SLC6A3—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.00016	0.00547	CbGpPWpGaD
Fluvoxamine—SIGMAR1—brain—attention deficit hyperactivity disorder	0.00016	0.0243	CbGeAlD
Fluvoxamine—SLC6A4—Circadian rythm related genes—DRD3—attention deficit hyperactivity disorder	0.000157	0.00539	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.000155	0.00532	CbGpPWpGaD
Fluvoxamine—SLC6A4—Circadian rythm related genes—DRD4—attention deficit hyperactivity disorder	0.000153	0.00523	CbGpPWpGaD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.00015	0.00513	CbGpPWpGaD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.000145	0.00495	CbGpPWpGaD
Fluvoxamine—SLC6A4—Circadian rythm related genes—DRD2—attention deficit hyperactivity disorder	0.000142	0.00487	CbGpPWpGaD
Fluvoxamine—CYP1A1—nervous system—attention deficit hyperactivity disorder	0.00014	0.0213	CbGeAlD
Fluvoxamine—CYP2B6—nervous system—attention deficit hyperactivity disorder	0.000136	0.0207	CbGeAlD
Fluvoxamine—CYP1A1—central nervous system—attention deficit hyperactivity disorder	0.000135	0.0205	CbGeAlD
Fluvoxamine—ABCB1—forebrain—attention deficit hyperactivity disorder	0.000134	0.0204	CbGeAlD
Fluvoxamine—CYP2B6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000134	0.00458	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.000134	0.00458	CbGpPWpGaD
Fluvoxamine—CYP2B6—central nervous system—attention deficit hyperactivity disorder	0.000131	0.02	CbGeAlD
Fluvoxamine—SLC6A3—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000131	0.00449	CbGpPWpGaD
Fluvoxamine—CYP2E1—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000131	0.00449	CbGpPWpGaD
Fluvoxamine—CYP3A5—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000131	0.00448	CbGpPWpGaD
Fluvoxamine—CYP2E1—nervous system—attention deficit hyperactivity disorder	0.000128	0.0195	CbGeAlD
Fluvoxamine—SLC6A3—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000125	0.00428	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.000124	0.00426	CbGpPWpGaD
Fluvoxamine—CYP1A1—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000124	0.00423	CbGpPWpGaD
Fluvoxamine—CYP2E1—central nervous system—attention deficit hyperactivity disorder	0.000123	0.0187	CbGeAlD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.000122	0.00418	CbGpPWpGaD
Fluvoxamine—CYP2E1—cerebellum—attention deficit hyperactivity disorder	0.00012	0.0183	CbGeAlD
Fluvoxamine—SLC6A3—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.000119	0.00408	CbGpPWpGaD
Fluvoxamine—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.000114	0.0173	CbGeAlD
Fluvoxamine—CYP1A1—brain—attention deficit hyperactivity disorder	0.000107	0.0163	CbGeAlD
Fluvoxamine—CYP2B6—brain—attention deficit hyperactivity disorder	0.000104	0.0158	CbGeAlD
Fluvoxamine—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000103	0.0157	CbGeAlD
Fluvoxamine—SLC6A3—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.000102	0.00351	CbGpPWpGaD
Fluvoxamine—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000101	0.0154	CbGeAlD
Fluvoxamine—CYP2C19—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000101	0.00346	CbGpPWpGaD
Fluvoxamine—CYP3A4—central nervous system—attention deficit hyperactivity disorder	9.91e-05	0.0151	CbGeAlD
Fluvoxamine—CYP2E1—brain—attention deficit hyperactivity disorder	9.78e-05	0.0149	CbGeAlD
Fluvoxamine—CYP2D6—central nervous system—attention deficit hyperactivity disorder	9.75e-05	0.0148	CbGeAlD
Fluvoxamine—CYP3A7—Biological oxidations—COMT—attention deficit hyperactivity disorder	9.69e-05	0.00332	CbGpPWpGaD
Fluvoxamine—CYP3A7—Biological oxidations—MAOA—attention deficit hyperactivity disorder	9.62e-05	0.00329	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	9.55e-05	0.00327	CbGpPWpGaD
Fluvoxamine—CYP2D6—cerebellum—attention deficit hyperactivity disorder	9.53e-05	0.0145	CbGeAlD
Fluvoxamine—SLC6A3—Neuronal System—SNAP25—attention deficit hyperactivity disorder	9.52e-05	0.00326	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	9.42e-05	0.00322	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	9.35e-05	0.0032	CbGpPWpGaD
Fluvoxamine—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	9.31e-05	0.00319	CbGpPWpGaD
Fluvoxamine—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	9.23e-05	0.00316	CbGpPWpGaD
Fluvoxamine—ABCB1—midbrain—attention deficit hyperactivity disorder	8.86e-05	0.0135	CbGeAlD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	8.15e-05	0.00279	CbGpPWpGaD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	8.15e-05	0.00279	CbGpPWpGaD
Fluvoxamine—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	7.88e-05	0.0027	CbGpPWpGaD
Fluvoxamine—CYP2D6—brain—attention deficit hyperactivity disorder	7.74e-05	0.0118	CbGeAlD
Fluvoxamine—ABCB1—nervous system—attention deficit hyperactivity disorder	7.29e-05	0.0111	CbGeAlD
Fluvoxamine—SLC6A3—Neuronal System—COMT—attention deficit hyperactivity disorder	7.22e-05	0.00247	CbGpPWpGaD
Fluvoxamine—CYP1A2—Phase II conjugation—COMT—attention deficit hyperactivity disorder	7.21e-05	0.00247	CbGpPWpGaD
Fluvoxamine—SLC6A3—Neuronal System—MAOA—attention deficit hyperactivity disorder	7.17e-05	0.00245	CbGpPWpGaD
Fluvoxamine—CYP2B6—Biological oxidations—COMT—attention deficit hyperactivity disorder	7.16e-05	0.00245	CbGpPWpGaD
Fluvoxamine—CYP2B6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	7.11e-05	0.00243	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	7.06e-05	0.00242	CbGpPWpGaD
Fluvoxamine—ABCB1—central nervous system—attention deficit hyperactivity disorder	7.02e-05	0.0107	CbGeAlD
Fluvoxamine—CYP2E1—Biological oxidations—COMT—attention deficit hyperactivity disorder	7.02e-05	0.0024	CbGpPWpGaD
Fluvoxamine—CYP3A5—Biological oxidations—COMT—attention deficit hyperactivity disorder	7e-05	0.0024	CbGpPWpGaD
Fluvoxamine—CYP2E1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	6.97e-05	0.00238	CbGpPWpGaD
Fluvoxamine—CYP3A5—Biological oxidations—MAOA—attention deficit hyperactivity disorder	6.95e-05	0.00238	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	6.92e-05	0.00237	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	6.91e-05	0.00236	CbGpPWpGaD
Fluvoxamine—ABCB1—cerebellum—attention deficit hyperactivity disorder	6.86e-05	0.0104	CbGeAlD
Fluvoxamine—CYP1A1—Biological oxidations—COMT—attention deficit hyperactivity disorder	6.61e-05	0.00226	CbGpPWpGaD
Fluvoxamine—CYP1A1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	6.57e-05	0.00225	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	6.52e-05	0.00223	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	6.52e-05	0.00223	CbGpPWpGaD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	6.47e-05	0.00221	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	6.22e-05	0.00213	CbGpPWpGaD
Fluvoxamine—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	6.08e-05	0.00208	CbGpPWpGaD
Fluvoxamine—ABCB1—brain—attention deficit hyperactivity disorder	5.57e-05	0.00847	CbGeAlD
Fluvoxamine—CYP2C19—Biological oxidations—COMT—attention deficit hyperactivity disorder	5.41e-05	0.00185	CbGpPWpGaD
Fluvoxamine—CYP2C19—Biological oxidations—MAOA—attention deficit hyperactivity disorder	5.37e-05	0.00184	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	5.34e-05	0.00183	CbGpPWpGaD
Fluvoxamine—SLC6A4—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	5.28e-05	0.00181	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	5.19e-05	0.00178	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	5.19e-05	0.00178	CbGpPWpGaD
Fluvoxamine—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	4.98e-05	0.0017	CbGpPWpGaD
Fluvoxamine—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	4.94e-05	0.00169	CbGpPWpGaD
Fluvoxamine—CYP2C9—Biological oxidations—COMT—attention deficit hyperactivity disorder	4.94e-05	0.00169	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	4.91e-05	0.00168	CbGpPWpGaD
Fluvoxamine—CYP2C9—Biological oxidations—MAOA—attention deficit hyperactivity disorder	4.9e-05	0.00168	CbGpPWpGaD
Fluvoxamine—ABCB1—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	4.87e-05	0.00167	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	4.87e-05	0.00167	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	4.65e-05	0.00159	CbGpPWpGaD
Fluvoxamine—CYP1A2—Biological oxidations—COMT—attention deficit hyperactivity disorder	4.22e-05	0.00144	CbGpPWpGaD
Fluvoxamine—CYP1A2—Biological oxidations—MAOA—attention deficit hyperactivity disorder	4.19e-05	0.00143	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	4.16e-05	0.00142	CbGpPWpGaD
Fluvoxamine—CYP1A1—PPARA activates gene expression—EP300—attention deficit hyperactivity disorder	4.06e-05	0.00139	CbGpPWpGaD
Fluvoxamine—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—attention deficit hyperactivity disorder	3.97e-05	0.00136	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.96e-05	0.00136	CbGpPWpGaD
Fluvoxamine—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	3.25e-05	0.00111	CbGpPWpGaD
Fluvoxamine—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	3.23e-05	0.00111	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	3.21e-05	0.0011	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.93e-05	0.001	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.87e-05	0.000982	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.86e-05	0.00098	CbGpPWpGaD
Fluvoxamine—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—attention deficit hyperactivity disorder	2.74e-05	0.000936	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.73e-05	0.000936	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—TPH2—attention deficit hyperactivity disorder	2.73e-05	0.000936	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.7e-05	0.000926	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—DPYD—attention deficit hyperactivity disorder	2.69e-05	0.000921	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.5e-05	0.000856	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	2.27e-05	0.000777	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.21e-05	0.000758	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.19e-05	0.000748	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.16e-05	0.00074	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	2.08e-05	0.000713	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.08e-05	0.000712	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.04e-05	0.000697	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—TPH2—attention deficit hyperactivity disorder	2.02e-05	0.000692	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.02e-05	0.000692	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.02e-05	0.000691	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—DPYD—attention deficit hyperactivity disorder	1.99e-05	0.000681	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—TPH2—attention deficit hyperactivity disorder	1.98e-05	0.000678	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.98e-05	0.000678	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—TPH2—attention deficit hyperactivity disorder	1.98e-05	0.000677	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.98e-05	0.000677	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—DPYD—attention deficit hyperactivity disorder	1.95e-05	0.000667	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—DPYD—attention deficit hyperactivity disorder	1.94e-05	0.000666	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—TPH2—attention deficit hyperactivity disorder	1.87e-05	0.000639	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.87e-05	0.000639	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.85e-05	0.000633	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—DPYD—attention deficit hyperactivity disorder	1.84e-05	0.000629	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.81e-05	0.00062	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.81e-05	0.000619	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.72e-05	0.00059	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.71e-05	0.000585	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—COMT—attention deficit hyperactivity disorder	1.66e-05	0.000567	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—MAOA—attention deficit hyperactivity disorder	1.64e-05	0.000563	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.62e-05	0.000553	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.58e-05	0.000542	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.58e-05	0.000541	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.54e-05	0.000527	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—TPH2—attention deficit hyperactivity disorder	1.53e-05	0.000523	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.53e-05	0.000523	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.51e-05	0.000516	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.5e-05	0.000515	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—DPYD—attention deficit hyperactivity disorder	1.5e-05	0.000515	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.49e-05	0.000511	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	1.49e-05	0.00051	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.49e-05	0.00051	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	1.47e-05	0.000502	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.42e-05	0.000486	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	1.41e-05	0.000481	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.41e-05	0.000481	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.4e-05	0.000478	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	1.39e-05	0.000477	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.39e-05	0.000477	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	1.38e-05	0.000473	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	1.37e-05	0.000469	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.36e-05	0.000467	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	1.33e-05	0.000456	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.29e-05	0.00044	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.27e-05	0.000436	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—COMT—attention deficit hyperactivity disorder	1.22e-05	0.000419	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.22e-05	0.000418	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—MAOA—attention deficit hyperactivity disorder	1.22e-05	0.000416	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—COMT—attention deficit hyperactivity disorder	1.2e-05	0.000411	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—COMT—attention deficit hyperactivity disorder	1.2e-05	0.00041	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.19e-05	0.000408	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—MAOA—attention deficit hyperactivity disorder	1.19e-05	0.000408	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	1.19e-05	0.000408	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.19e-05	0.000408	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—MAOA—attention deficit hyperactivity disorder	1.19e-05	0.000407	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	1.17e-05	0.000401	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.16e-05	0.000398	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.13e-05	0.000389	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—COMT—attention deficit hyperactivity disorder	1.13e-05	0.000387	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.12e-05	0.000385	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—MAOA—attention deficit hyperactivity disorder	1.12e-05	0.000384	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.11e-05	0.000381	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	1.09e-05	0.000373	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.09e-05	0.000373	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.07e-05	0.000366	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.06e-05	0.000363	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	9.52e-06	0.000326	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—COMT—attention deficit hyperactivity disorder	9.26e-06	0.000317	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—MAOA—attention deficit hyperactivity disorder	9.19e-06	0.000315	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	9.19e-06	0.000315	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	9.19e-06	0.000315	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	9.06e-06	0.00031	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	9.04e-06	0.000309	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	9.03e-06	0.000309	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	8.97e-06	0.000307	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	8.91e-06	0.000305	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	8.51e-06	0.000291	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	8.45e-06	0.000289	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	8.44e-06	0.000289	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	8.4e-06	0.000288	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	8.38e-06	0.000287	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	8.13e-06	0.000278	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	7.34e-06	0.000251	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	7.21e-06	0.000247	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	7.16e-06	0.000245	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—EP300—attention deficit hyperactivity disorder	7.1e-06	0.000243	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	6.99e-06	0.000239	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	6.95e-06	0.000238	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	5.57e-06	0.000191	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	5.53e-06	0.000189	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—EP300—attention deficit hyperactivity disorder	5.25e-06	0.00018	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—EP300—attention deficit hyperactivity disorder	5.15e-06	0.000176	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—EP300—attention deficit hyperactivity disorder	5.13e-06	0.000176	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—EP300—attention deficit hyperactivity disorder	4.85e-06	0.000166	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—EP300—attention deficit hyperactivity disorder	3.97e-06	0.000136	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	3.87e-06	0.000133	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	3.65e-06	0.000125	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	3.62e-06	0.000124	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	3.09e-06	0.000106	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	2.39e-06	8.17e-05	CbGpPWpGaD
